Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate effect of [11C]MK-6884 PET Tracer for M4 Muscarinic Cholinergic Receptors in Alzheimer's Disease patients in comparison with [18F]FDG PET

Trial Profile

A study to evaluate effect of [11C]MK-6884 PET Tracer for M4 Muscarinic Cholinergic Receptors in Alzheimer's Disease patients in comparison with [18F]FDG PET

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 6884 (Primary) ; Fludeoxyglucose F-18
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 22 Apr 2021 Results of MK-6884 PET Tracer for M4 Muscarinic Cholinergic Receptors in Alzheimers Disease, presented at the 73rd Annual Meeting of the American Academy of Neurology
    • 21 May 2020 New trial record
    • 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top